Selexis is a Switzerland-based biotech company

Selexis SA
Chemin des Aulx 18
1228
Plan-les-Ouates
1228 Plan-les-Ouates
Auf Karte anzeigen
022 884 83 42
022 794 66 65
info@selexis.com
www.selexis.com
Öffnungszeiten
MO - FR: 08:00 - 18:00
Firmenbeschrieb
Selexis SA is offering a unique and proprietary product, called MARtech that allows the industry to drastically decrease the manufacturing costs associated with the production of recombinant protein drugs (i.e. monoclonal antibodies). Based on MARtech, Selexis also offers to rapidly establish (3 months) very high producing mammalian cell lines.Gründungsjahr
2001
Anzahl Mitarbeiter
8
MwSt-Nr
CHE-102.097.821
Unser Team
Igor Fisch
PhDCEO
Nicolas Mermod
PhDboard of directors. R&D
Peter Pfister
board of directors,Marktleistungen
-
MARtech
Selexis has developed a superior technology that boosts eukaryotic recombinant protein production processes. The technology is based on the observation that genetic elements involved in the dynamic of chromatin called Matrix Attachment Regions (MARs) are pivotal for heritable transmission of gene expression patterns. MARs have been shown to be associated with remodeling of the surrounding chromatin, thus promoting transgene expression in the form of an active artificial transcriptional domain. MAR elements are highly active when a transgene cassette co-integrated within the chromosome of the eukaryotic host cell (stable expression mode). MAR elements have also been shown to be active when a transgene cassette is not integrated (transient expression mode). These features make MARtech extremely valuable in different areas of the biotechnology industry that relies on the production of human recombinant protein targets for drug discovery or on the production of therapeutic proteins (e.g. antibodies). To date, Selexis has signed several contracts with major Pharmaceutical and Biotechnology companies in order to enhance the production of recombinant protein drugs.
-
Drug dicovery platform
Selexis has developed an original drug discovery platform that combines its proprietary technology MARtech for the rapid production of human recombinant protein targets with a powerful selection tool to rapidly identify hit compounds against the protein targets. These hits are further evolved towards leads by using recombinant DNA techniques. The potential lead compounds are then assayed in vivo in pre-clinical tests using cell culture and mice bearing human tumor xenografts.
Eintrag erstellt: 10.09.2004, Letzte Änderung: 18.02.2009

